Table 1 Metaplastic breast cancer cohort.

From: Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1

 

n

%

Age

  <50

40

28.8

  >51

99

71.2

  Total

139

 

Size

  <2 cm

31

21.4

  2–5 cm

82

56.6

  >5 cm

32

22.1

 Total

145

 

WHO Type

  1 (mixed)

116

71.6

  2 (low‐grade adenosquamous)

1

0.6

  3 (fibromatosis‐like)

4

2.5

  4 (squamous)

25

15.4

  5 (spindle)

14

8.6

  6 (mesenchymal)

2

1.2

  Total

162

 

ER/PR/HER2

  TNBC

85

64.4

  ER/PR pos

8

6.1

  ER pos

13

9.8

  PR pos

13

9.8

  HER2 pos

13

9.8

  Total

132

 

TILs

  Grp 1: 0–10%

75

49.3

  Grp 2: 20–40%

62

40.8

  Grp 3: 50–90%

15

9.9

  total

152

 

PD-L1 tumour cells

  Positive

107

73

  Negative

39

27

  Total

146

 

PD-L1 TILs

  Positive

91

63

  Negative

53

37

  Total

144

 

FOXP3 sTILs

  Positive

73

49

  Negative

76

51

  Total

149

 

FOXP3 iTILs

  Positive

57

38

  Negative

93

62

  Total

150